NASDAQ:HOWL

Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update
·····

Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update

Werewolf Therapeutics shares traded near $0.45 Monday, close to a 52-week low, after entities tied to director Luke Evnin sold 141,106 shares under a preset plan, SEC filings show. The company remains under strategic review following a deal with Jazz Pharmaceuticals and repayment of K2 HealthVentures debt. Werewolf reported $46.5 million in cash as of March 31 but warned of “substantial doubt” about its ability to continue as a going concern.
June 1, 2026

Stock Market Today

  • ASX Stocks Positioned to Endure Market and Economic Changes
    June 1, 2026, 8:15 PM EDT. This article discusses Australian Securities Exchange (ASX) stocks with strong potential to withstand decades of market volatility and economic shifts. It highlights the importance of companies with solid fundamentals and resilient business models that can adapt to changing conditions. The piece cautions that the content is for informational purposes only and does not serve as investment advice. Investors are urged to conduct their own research and seek guidance from qualified financial professionals. Emphasizing prudence, the article notes that past performance is not indicative of future results and advises consultation with advisers on tax, legal, and financial matters.